Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amic AB

Division of Johnson & Johnson
www.amic.se

Latest From BeiGene (Beijing) Co. Ltd.

Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard (Part 2)

Howard Liang comes from an investment background with years of experience honed being the former managing director and head of biotech equity research at Leerink Partners. He became Beigene's CFO and Chief Strategy Officer in 2015 as the biotech prepared for its initial public offering (IPO) on Nasdaq, and has since seen the Beijing-based firm leap onto the world stage with differentiated immuno-oncology and BTK inhibitor assets.

Commercial BioPharmaceutical

Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard

Howard Liang comes from an investment background with years of experience honed as the former managing director and head of biotech equity research at Leerink Partners. He became Beigene's CFO and Chief Strategy Officer in 2015 as the Chinese biotech prepared for its initial public offering on Nasdaq, and has since seen the Beijing-based firm leap onto the world stage with differentiated immuno-oncology and BTK inhibitor assets.

Commercial BioPharmaceutical

Pipeline Watch: Phase III Starts With Mogamulizumab, AR101 And Vilaprisan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea

Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Ove Ohman, PhD, CEO
    Christer Samuelsson, CFO
    Mike Read, PhD, VP, Bus. Dev.
    Ib Mendel-Hartvig, PhD, VP, Prod. Dev.
  • Contact Info
  • Amic AB
    Phone: (46) 18 52 16 40
    Dag Hammarskjolds vag 52B
    Uppsala, SE-751 83
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register